Sarah J Lord

Summary

Affiliation: University of Sydney
Country: Australia

Publications

  1. ncbi request reprint When is measuring sensitivity and specificity sufficient to evaluate a diagnostic test, and when do we need randomized trials?
    Sarah J Lord
    National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Sydney, Camperdown, NSW, Australia
    Ann Intern Med 144:850-5. 2006
  2. pmc Expenditure and resource utilisation for cervical screening in Australia
    Jie Bin Lew
    Cancer Research Division, Cancer Council NSW, 153 Dowling Street, Woolloomooloo, Sydney, NSW 2011, Australia
    BMC Health Serv Res 12:446. 2012
  3. pmc Cervical cancer screening in Australia: modelled evaluation of the impact of changing the recommended interval from two to three years
    Prudence Creighton
    Cancer Epidemiology Research Unit, Cancer Council NSW, Sydney, Australia
    BMC Public Health 10:734. 2010
  4. pmc Polymorphisms in genes involved in estrogen and progesterone metabolism and mammographic density changes in women randomized to postmenopausal hormone therapy: results from a pilot study
    Sarah J Lord
    Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
    Breast Cancer Res 7:R336-44. 2005
  5. pmc Breast cancer risk and hormone receptor status in older women by parity, age of first birth, and breastfeeding: a case-control study
    Sarah J Lord
    National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia
    Cancer Epidemiol Biomarkers Prev 17:1723-30. 2008
  6. ncbi request reprint Incidence of metastatic breast cancer in an Australian population-based cohort of women with non-metastatic breast cancer at diagnosis
    Sarah J Lord
    National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, NSW
    Med J Aust 196:688-92. 2012
  7. pmc Using patient management as a surrogate for patient health outcomes in diagnostic test evaluation
    Lukas P Staub
    NHMRC Clinical Trials Centre, The University of Sydney, Sydney, Australia
    BMC Med Res Methodol 12:12. 2012
  8. ncbi request reprint Breast cancer screening: emerging role of new imaging techniques as adjuncts to mammography
    Nehmat Houssami
    Screening and Test Evaluation Program, School of Public Health, Faculty of Medicine, University of Sydney, Sydney, NSW, Australia
    Med J Aust 190:493-7. 2009
  9. ncbi request reprint Cost analysis of Gamma Knife stereotactic radiosurgery
    Alison Griffiths
    NHMRC Clinical Trials Centre, University of Sydney, Camperdown, New South Wales 2050, Austria
    Int J Technol Assess Health Care 23:488-94. 2007
  10. ncbi request reprint Value of magnetic resonance cholangiopancreatography in the diagnosis of biliary abnormalities in postcholecystectomy patients: a probabilistic cost-effectiveness analysis of diagnostic strategies
    Kirsten Howard
    School of Public Health, University of Sydney, New South Wales, Australia
    Int J Technol Assess Health Care 22:109-18. 2006

Detail Information

Publications20

  1. ncbi request reprint When is measuring sensitivity and specificity sufficient to evaluate a diagnostic test, and when do we need randomized trials?
    Sarah J Lord
    National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Sydney, Camperdown, NSW, Australia
    Ann Intern Med 144:850-5. 2006
    ....
  2. pmc Expenditure and resource utilisation for cervical screening in Australia
    Jie Bin Lew
    Cancer Research Division, Cancer Council NSW, 153 Dowling Street, Woolloomooloo, Sydney, NSW 2011, Australia
    BMC Health Serv Res 12:446. 2012
    ..This study aimed to provide a baseline for such a review by quantifying screening program resource utilisation and costs in 2010...
  3. pmc Cervical cancer screening in Australia: modelled evaluation of the impact of changing the recommended interval from two to three years
    Prudence Creighton
    Cancer Epidemiology Research Unit, Cancer Council NSW, Sydney, Australia
    BMC Public Health 10:734. 2010
    ..The aim of the current evaluation was to assess the epidemiologic outcomes and cost implications of changing the recommended screening interval in Australia to 3 years...
  4. pmc Polymorphisms in genes involved in estrogen and progesterone metabolism and mammographic density changes in women randomized to postmenopausal hormone therapy: results from a pilot study
    Sarah J Lord
    Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
    Breast Cancer Res 7:R336-44. 2005
    ..Identifying genetic variants that determine increases in mammographic density in hormone users may be important in understanding hormonal carcinogenesis of the breast...
  5. pmc Breast cancer risk and hormone receptor status in older women by parity, age of first birth, and breastfeeding: a case-control study
    Sarah J Lord
    National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia
    Cancer Epidemiol Biomarkers Prev 17:1723-30. 2008
    ..Early age at first birth and multiparity reduce the risk of estrogen receptor-progesterone receptor (ERPR)-positive breast cancer, whereas breastfeeding reduces the risk of both ERPR-positive and ERPR-negative cancers...
  6. ncbi request reprint Incidence of metastatic breast cancer in an Australian population-based cohort of women with non-metastatic breast cancer at diagnosis
    Sarah J Lord
    National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, NSW
    Med J Aust 196:688-92. 2012
    ..To estimate the incidence of metastatic breast cancer (MBC) in Australian women with an initial diagnosis of non-metastatic breast cancer...
  7. pmc Using patient management as a surrogate for patient health outcomes in diagnostic test evaluation
    Lukas P Staub
    NHMRC Clinical Trials Centre, The University of Sydney, Sydney, Australia
    BMC Med Res Methodol 12:12. 2012
    ..There is a lack of guidance on the interpretation of this evidence, and patient management studies often neglect a discussion of the limitations of measuring patient management as a surrogate for health outcomes...
  8. ncbi request reprint Breast cancer screening: emerging role of new imaging techniques as adjuncts to mammography
    Nehmat Houssami
    Screening and Test Evaluation Program, School of Public Health, Faculty of Medicine, University of Sydney, Sydney, NSW, Australia
    Med J Aust 190:493-7. 2009
    ..Emerging evidence and improved CAD technology are likely to help define its role in breast screening...
  9. ncbi request reprint Cost analysis of Gamma Knife stereotactic radiosurgery
    Alison Griffiths
    NHMRC Clinical Trials Centre, University of Sydney, Camperdown, New South Wales 2050, Austria
    Int J Technol Assess Health Care 23:488-94. 2007
    ..However, some countries including Australia have not recommended additional reimbursement for dedicated systems. This study compares the costs of Linac radiosurgery with Gamma Knife radiosurgery...
  10. ncbi request reprint Value of magnetic resonance cholangiopancreatography in the diagnosis of biliary abnormalities in postcholecystectomy patients: a probabilistic cost-effectiveness analysis of diagnostic strategies
    Kirsten Howard
    School of Public Health, University of Sydney, New South Wales, Australia
    Int J Technol Assess Health Care 22:109-18. 2006
    ..A model was constructed to compare the effectiveness and cost-effectiveness of MRCP and ERCP in patients with a previous history of cholecystectomy, presenting with abdominal pain and/or abnormal liver function tests...
  11. doi request reprint Systematic review of the impact of endoscopic ultrasound on the management of patients with esophageal cancer
    Suzanne M Dyer
    NHMRC Clinical Trials Centre, The University of Sydney, Camperdown, NSW, Australia
    Int J Technol Assess Health Care 24:25-35. 2008
    ..This study aims to determine the impact of EUS for esophageal cancer staging on patient management and survival...
  12. doi request reprint Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer
    Chee K Lee
    NHMRC Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, Sydney, NSW 1450, Australia
    J Natl Cancer Inst 103:1338-42. 2011
    ..80, 95% CI = 0.68 to 0.94, P = .007). These findings are opposite to what would be expected if these markers were good surrogates for treatment benefit...
  13. doi request reprint A cost-effectiveness analysis of in-vitro fertilization by maternal age and number of treatment attempts
    Alison Griffiths
    NHMRC Clinical Trials Centre, The University of Sydney, Camperdown, NSW 2050, Australia
    Hum Reprod 25:924-31. 2010
    ..A decision analytic model was designed to estimate the incremental cost-effectiveness of IVF by additional treatment programmes and maternal age...
  14. doi request reprint Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric cancer
    Nehmat Houssami
    Screening and Test Evaluation Program, School of Public Health, University of Sydney, Sydney, Australia
    J Clin Oncol 26:3248-58. 2008
    ..Randomized trials are needed to determine the clinical value of detecting additional disease which changes surgical treatment in women with apparently localized breast cancer...
  15. ncbi request reprint Molecular biomarkers to individualise treatment: assessing the evidence
    Chee K Lee
    NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW
    Med J Aust 190:631-6. 2009
    ....
  16. ncbi request reprint Risk assessment to guide prostate cancer screening decisions: a cost-effectiveness analysis
    Andrew J Martin
    NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia
    Med J Aust 198:546-50. 2013
    ..To apply the most recent evidence from randomised trials of prostate-specific antigen (PSA) screening and explore the potential value of risk assessments to guide the use of PSA screening in practice...
  17. doi request reprint Using the principles of randomized controlled trial design to guide test evaluation
    Sarah J Lord
    National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, NSW 2050, Australia
    Med Decis Making 29:E1-E12. 2009
    ..Long-term RCTs will not be necessary if it is valid to use other sources of evidence to address these questions. Validity will depend on issues such as the spectrum of patients identified by the old and new test strategies...
  18. ncbi request reprint What is the value of computered tomography colonography in patients screening positive for fecal occult blood? A systematic review and economic evaluation
    Silke Walleser
    National Health and Medical Research Council Clinical Trials Centre, University of Sydney, New South Wales, Australia
    Clin Gastroenterol Hepatol 5:1439-46; quiz 1368. 2007
    ..Because of high false-positive rates for FOBT, concerns have been raised about patient uptake and access to colonoscopy services. This study assessed the value of CTC as an alternative to colonoscopy in FOBT-positive individuals...
  19. ncbi request reprint A systematic review and economic analysis of drug-eluting coronary stents available in Australia
    Sarah J Lord
    National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, NSW 2050, Australia
    Med J Aust 183:464-71. 2005
    ..To compare the safety, effectiveness and cost-effectiveness of drug-eluting coronary stents used in Australia with bare-metal stents and determine whether the benefits are greater for high-risk subgroups...
  20. ncbi request reprint Reproductive factors and risk of breast carcinoma in a study of white and African-American women
    Giske Ursin
    Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California 90089, USA
    Cancer 101:353-62. 2004
    ....